THE HIV NETHERLANDS AUSTRALIA THAILAND RESEARCH COLLABORATION

🇹🇭Thailand

Country: 🇹🇭Thailand

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Thailand HDV Cohort

Recruiting

Conditions: HDV

First Posted Date: 2022-04-28

Last Posted Date: 2024-10-02

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 3152

Registration Number: NCT05350865

Locations: 🇹🇭
Siriraj Hospital, Mahidol University, Bangkok, Thailand
🇹🇭
King memorial Chulalongkorn hospital, Bangkok, Thailand
🇹🇭
HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok, Thailand

and more 1 locations

Microneedles for Diagnosis of LTBI

Not Applicable

Terminated

Conditions: Latent Tuberculosis

Interventions: Diagnostic Test: TST vs PPD microneedle test

First Posted Date: 2020-09-17

Last Posted Date: 2023-03-01

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 4

Registration Number: NCT04552015

Locations: 🇹🇭
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Self-Assessment Tuberculin Skin Test

Completed

Conditions: Tuberculin Skin Test

Interventions: Other: The participants do not receive any intervention for this study

First Posted Date: 2019-02-11

Last Posted Date: 2020-07-16

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 215

Registration Number: NCT03835832

Locations: 🇹🇭
Taksin Hospital, Bangkok, Thailand
🇹🇭
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Phase 3

Active, not recruiting

Conditions: HIV-infected Participants With Latent TB Infection in High TB Burden Country

Interventions: Drug: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Drug: Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

First Posted Date: 2018-12-24

Last Posted Date: 2024-02-28

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 2500

Registration Number: NCT03785106

Locations: 🇹🇭
Bhumibol Adulyadej Hospital, Bangkok, Thailand
🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭
Sanpatong Hospital, Chiang Mai, Thailand

and more 13 locations

Efficacy, Safety and Pharmacokinetics of DTG with RIF

Phase 2

Recruiting

Conditions: HIV/TB Coinfection

Interventions: Drug: DTG 50 mg OD with food
Drug: DTG 50 mg BID

First Posted Date: 2018-11-06

Last Posted Date: 2024-10-02

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 200

Registration Number: NCT03731559

Locations: 🇹🇭
Infectious Disease Chiangrai Prachanukroh Hospital, Chiang Rai, Chiangrai, Thailand
🇹🇭
Klang Hospital, Bangkok, Thailand
🇹🇭
Bhumibol Adulyadej Hospital, Bangkok, Thailand

and more 7 locations

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

Phase 3

Completed

Conditions: HIV

Interventions: Drug: generic single tablet TAF/FTC/DTG

First Posted Date: 2018-11-01

Last Posted Date: 2024-02-28

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 170

Registration Number: NCT03727152

Locations: 🇹🇭
Police General Hospital, Bangkok, Thailand
🇹🇭
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals

Not Applicable

Active, not recruiting

Conditions: Tuberculosis

Interventions: Diagnostic Test: XpertMTB/RIF

First Posted Date: 2017-02-03

Last Posted Date: 2024-02-28

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 150

Registration Number: NCT03042754

Locations: 🇹🇭
Bamrasnaradura Institute, Nonthaburi, Thailand
🇹🇭
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
🇹🇭
Chulalongkorn University, Bangkok, Thailand

and more 1 locations

Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

Phase 4

Conditions: Compensated Cirrhosis

Interventions: Drug: Grazaoprevir/Elbasavir
Drug: Grazaoprevir/Elbasavir/RBV

First Posted Date: 2017-01-31

Last Posted Date: 2020-02-13

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 100

Registration Number: NCT03037151

Locations: 🇹🇭
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
🇹🇭
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

RH and Adolescents

Completed

Conditions: Reproductive Health

Interventions: Other: reversible contraceptive methods

First Posted Date: 2016-03-21

Last Posted Date: 2016-03-21

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 77

Registration Number: NCT02713750

Locations: 🇹🇭
HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
🇹🇭
Phramongkutklao Hospital of The Royal Thai Army, Bangkok, Thailand
🇹🇭
Phachomklao Hospital, Petchaburi, Thailand

and more 1 locations

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly

Phase 2

Completed

Conditions: HIV
Tuberculosis

Interventions: Drug: Lopinavir/r will be supplied by NHSO/GPO
Drug: Rifabutin

First Posted Date: 2015-04-14

Last Posted Date: 2020-02-12

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 40

Registration Number: NCT02415985

Locations: 🇹🇭
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
🇹🇭
HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok, Thailand
🇹🇭
Chest Division, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy